Multicompartmental, multilayered probucol microcapsules for diabetes mellitus: Formulation characterization and effects on production of insulin and inflammation in a pancreatic β-cell line

Artificial Cells, Nanomedicine and Biotechnology

Volumn 44, Issue 7, 2016, Pages 1642-1653

  Mooranian, Armin ^a   Negrulj, Rebecca ^a   Arfuso, Frank ^a   Al Salami, Hani ^a  

^a CURTIN UNIVERSITY   (Australia)

Author keywords

artificial cell microencapsulation; bile acids; diabetes mellitus; inflammation; NIT 1 cells; probucol

Indexed keywords

ACETONE; BODY FLUIDS; CELL CULTURE; CELLS; CHEMICAL STABILITY; COMPUTERIZED TOMOGRAPHY; CYTOLOGY; DIFFERENTIAL SCANNING CALORIMETRY; ENERGY DISPERSIVE SPECTROSCOPY; FOURIER TRANSFORM INFRARED SPECTROSCOPY; INSULIN; MICROSTRUCTURE; PATHOLOGY; SCANNING ELECTRON MICROSCOPY; X RAY SPECTROSCOPY;

ARTIFICIAL CELL; BILE ACID; DIABETES MELLITUS; INFLAMMATION; PROBUCOL;

ENCAPSULATION;

ALGINIC ACID; BILE ACID; CHOLIC ACID; EXCIPIENT; INSULIN; PROBUCOL; TUMOR NECROSIS FACTOR; MICROCAPSULE;

ARTICLE; BIOLOGICAL ACTIVITY; CELL VIABILITY; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; ENERGY DISPERSIVE X RAY SPECTROSCOPY; IN VITRO STUDY; INFLAMMATION; INFRARED SPECTROSCOPY; INSULIN RELEASE; MICRO-COMPUTED TOMOGRAPHY; MICROCAPSULE; PANCREAS ISLET BETA CELL; SCANNING ELECTRON MICROSCOPY; VISCOSITY; ZETA POTENTIAL; ANIMAL; CELL LINE; CELL SURVIVAL; CHEMISTRY; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEM; DRUG EFFECTS; METABOLISM; MOUSE; PATHOLOGY; PROCEDURES;

ANIMALS; CAPSULES; CELL LINE; CELL SURVIVAL; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; INFLAMMATION; INSULIN; INSULIN-SECRETING CELLS; MICE; PROBUCOL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84986296813     PISSN: 21691401     EISSN: 2169141X     Source Type: Journal    
DOI: 10.3109/21691401.2015.1069299     Document Type: Article

References (72)

1. W.Ajun, S.Yan, G.Li, L.Huili. 2009. Preparation of aspirin and probucol in combination loaded chitosan nanoparticles and in vitro release study. Carbohydr Polym. 75:566–574.
2. R.S.Al-Kassas, O.Al-Gohary, M.M.Al-Faadhel. 2007. Controlling of systemic absorption of gliclazide through incorporation into alginate beads. Int J Pharma. 341:230–237.
3. H.Al-Salami, G.Butt, I.Tucker, P.J.Fawcett, S.Golocorbin-Kon, I.Mikov, M.Mikov. 2009. Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet. 34:43–50.
4. H.Al-Salami, G.Butt, I.Tucker, S.Golocorbin-Kon, M.Mikov. 2012. Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet. 37:99–108.
5. H.Al-Salami, G.Butt, I.Tucker, M.Mikov. 2008a. Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics. Methods Find Exp Clin Pharmacol. 30:107–113.
6. H.Al-Salami, G.Butt, I.Tucker, R.Skrbic, S.Golocorbin-Kon, M.Mikov. 2008b. Probiotic Pre-treatment Reduces Gliclazide Permeation (ex vivo) in Healthy Rats but Increases It in Diabetic Rats to the Level Seen in Untreated Healthy Rats. Arch Drug Inf. 1:35–41.
7. H.Al-Salami, G.Butt, I.G.Tucker, M.Mikov. 2008c. The Influence of Pre-Treatment with Probiotics on the in Vitro Ileal Permeation of the Antidiabetic Drug Gliclazide, in Healthy and Diabetic Rats. Drug Metabol Rev. 40:81–82.
8. H.Al-Salami, B.Grant, T.Ian, M.Mikov. 2008d. The influence of probiotics pre-treatment, on the ileal permeation of gliclazide, in healthy and diabetic rats. Arch Drug Inf. 1:35–41.
9. M.Altaf. 2008. Ionic gelation controlled drug delivery systems for gastric-mucoadhesive microcapsules of captopril. Indian J Pharm Sci. 70:655.
10. E.Andersen, G.Karlaganis, J.Sjovall. 1988. Altered bile acid profiles in duodenal bile and urine in diabetic subjects. Eur J Clin Invest. 18:166–172.
11. D.R.Arifin, C.M.Long, A.A.Gilad, C.Alric, S.Roux, O.Tillement,. 2011. Trimodal gadolinium-gold microcapsules containing pancreatic islet cells restore normoglycemia in diabetic mice and can be tracked by using US, CT, and positive-contrast MR imaging. Radiology. 260:790–798.
12. D.R.Arifin, S.Manek, E.Call, A.Arepally, J.W.Bulte. 2012. Microcapsules with intrinsic barium radiopacity for immunoprotection and X-ray/CT imaging of pancreatic islet cells. Biomaterials. 33:4681–4689.
13. R.Awasthi, G.T.Kulkarni. 2012. Development of novel gastroretentive floating particulate drug delivery system of gliclazide. Curr Drug Deliv. 9:437–451.
14. R.Awasthi, G.T.Kulkarni. 2013. Development of novel gastroretentive drug delivery system of gliclazide:hollow beads. Drug Dev Ind Pharm. 1–11.
15. R.Barnett. 2010. Historical keyword:diabetes. Lancet. 375:191.
16. A.K.Batta, S.K.Aggarwal, G.Salen, S.Shefer. 1991. Selective reduction of oxo bile acids:synthesis of 3 beta-, 7 beta-, and 12 beta-hydroxy bile acids. J Lipid Res. 32:977–983.
17. C.A.Bonino, J.E.Samorezov, O.Jeon, E.Alsberg, S.A.Khan. 2011. Real-time in situ rheology of alginate hydrogel photocrosslinking. Soft Matter. 7:11510–11517.
18. M.M.Buckley, K.L.Goa, A.H.Price, R.N.Brogden. 1989. Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia. Drugs. 37:761–800.
19. M.T.Cook, G.Tzortzis, D.Charalampopoulos, V.V.Khutoryanskiy. 2012. Microencapsulation of probiotics for gastrointestinal delivery. J Control Release. 162:56–67.
20. J.Davignon. 1990. Probucol revisited. In: G.Descovich, A.Gaddi, G.Magri & S.Lenzi (eds.) Atherosclerosis and Cardiovascular Disease. Springer Netherlands.
21. J.Davignon. 1994. Probucol. Principles and Treatment of Lipoprotein Disorders. Springer.
22. B.De Celis Alonso, P.Rayment, E.Ciampi, S.Ablett, L.Marciani, R.C.Spiller,. 2010. NMR relaxometry and rheology of ionic and acid alginate gels. Carbohydr Polym. 82:663–669.
23. K.I.Draget, C.Taylor. 2011. Chemical, physical and biological properties of alginates and their biomedical implications. Food Hydrocolloids. 25:251–256.
24. M.Düfer, K.Hörth, R.Wagner, B.Schittenhelm, S.Prowald, T.F.Wagner,. 2012. Bile Acids Acutely Stimulate Insulin Secretion of Mouse β-Cells via Farnesoid X Receptor Activation and KATP Channel Inhibition. Diabetes. 61:1479–1489.
25. M.Fakhoury, M.Coussa-Charley, H.Al-Salami, I.Kahouli, S.Prakash. 2014a. Use of artificial cell microcapsule containing thalidomide for treating TNBS-induced Crohn's disease in mice. Curr Drug Deliv. 11:146–153.
26. M.Fakhoury, R.Negrulj, A.Mooranian, H.Al-Salami. 2014b. Inflammatory bowel disease:clinical aspects and treatments. J Inflamm Res. 7:113–120.
27. D.Festi, R.Schiumerini, C.Birtolo, L.Marzi, L.Montrone, E.Scaioli,. 2011. Gut microbiota and its pathophysiology in disease paradigms. Dig Dis. 29:518–524.
28. M.Fukuda, H.Ikegami, Y.Kawaguchi, T.Sano, T.Ogihara. 1995. Antioxidant, probucol, can inhibit the generation of hydrogen peroxide in islet cells induced by macrophages and prevent islet cell destruction in NOD mice. Biochem Biophys Res Commun. 209:953–958.
29. M.George, T.E.Abraham. 2006. Polyionic hydrocolloids for the intestinal delivery of protein drugs:alginate and chitosan–a review. J Control Release. 114:1–14.
30. P.Gill, T.T.Moghadam, B.Ranjbar. 2010. Differential scanning calorimetry techniques:applications in biology and nanoscience. J Biomol Tech. 21:167–193.
31. C.H.Goh, P.W.S.Heng, L.W.Chan. 2012. Alginates as a useful natural polymer for microencapsulation and therapeutic applications. Carbohydr Polym. 88:1–12.
32. S.Gorogawa, Y.Kajimoto, Y.Umayahara, H.Kaneto, H.Watada, A.Kuroda,. 2002. Probucol preserves pancreatic beta-cell function through reduction of oxidative stress in type 2 diabetes. Diabetes Res Clin Pract. 57:1–10.
33. K.Hamaguchi, H.R.Gaskins, E.H.Leiter. 1991. NIT-1, a pancreatic beta-cell line established from a transgenic NOD/Lt mouse. Diabetes. 40:842–849.
34. J.F.Heeg, M.F.Hiser, D.K.Satonin, J.Q.Rose. 1984. Pharmacokinetics of probucol in male rats. J Pharm Sci. 73:1758–1763.
35. R.C.Heel, R.N.Brogden, T.M.Speight, G.S.Avery. 1978. Probucol:a review of its pharmacological properties and therapeutic use in patients with hypercholesterolaemia. Drugs. 15:409–428.
36. J.Kandrac, S.Kevresan, J.K.Gu, M.Mikov, J.P.Fawcett, K.Kuhajda. 2006. Isolation and determination of bile acids. Eur J Drug Metab Pharmacokinet. 31:157–177.
37. U.Karunakaran, K.G.Park. 2013. A systematic review of oxidative stress and safety of antioxidants in diabetes:focus on islets and their defense. Diabetes Metab J. 37:106–112.
38. A.R.Kulkarni, K.S.Soppimath, T.M.Aminabhavi, W.E.Rudzinski. 2001. In-vitro release kinetics of cefadroxil-loaded sodium alginate interpenetrating network beads. Eur J Pharm Biopharm. 51:127–133.
39. J.Legrand, E.Dumont, J.Comiti, F.Fayolle. 2000. Diffusion coefficients of ferricyanide ions in polymeric solutions—comparison of different experimental methods. Electrochimica acta. 45:1791–1803.
40. S.Y.Lin, S.L.Wang. 2012. Advances in simultaneous DSC-FTIR microspectroscopy for rapid solid-state chemical stability studies:some dipeptide drugs as examples. Adv Drug Deliv Rev. 64:461–478.
41. J.H.Liu, D.F.Liu, N.N.Wang, H.L.Lin, X.Mei. 2011. Possible role for the thioredoxin system in the protective effects of probucol in the pancreatic islets of diabetic rats. Clin Exp Pharmacol Physiol. 38:528–533.
42. A.C.Maritim, R.A.Sanders, J.B.Watkins, 3rd. 2003. Diabetes, oxidative stress, and antioxidants:a review. J Biochem Mol Toxicol. 17:24–38.
43. A.Mooranian, R.Negrulj, H.S.Al-Sallami, Z.Fang, M.Mikov, S.Golocorbin-Kon,. 2014a. Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment. J Microencapsul. 1–6.
44. A.Mooranian, R.Negrulj, F.Arfuso, H.Al-Salami. 2014b. Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic β-cells. Artificial Cells Nanomed Biotechnol. 1–7.
45. A.Mooranian, R.Negrulj, N.Chen-Tan, H.S.Al-Sallami, Z.Fang, T.Mukkur,. 2014c. Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation:a characterization study. Drug Des Dev Ther. 8:1003.
46. A.Mooranian, R.Negrulj, N.Chen-Tan, H.S.Al-Sallami, Z.Fang, T.K.Mukkur,. 2014d. Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol. Drug Des Devel Ther. 8:1221–1230.
47. A.Mooranian, R.Negrulj, N.Chen-Tan, G.F.Watts, F.Arfuso, H.Al-Salami. 2014e. An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer. Drug Des Devel Ther. 8:1673–1683.
48. A.Mooranian, R.Negrulj, S.Mathavan, J.Martinez, J.Sciarretta, N.Chen-Tan,. 2014f. Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation:The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics. J Pharm Innov. 9:150–157.
49. A.Mooranian, R.Negrulj, S.Mathavan, J.Martinez, J.Sciarretta, N.Chen-Tan,. 2014g. An advanced microencapsulated system:a platform for optimized oral delivery of antidiabetic drug-bile acid formulations. Pharm Dev Technol. 1–8.
50. A.Mooranian, R.Negrulj, H.S.Al-Sallami, Z.Fang, M.Mikov, S.Golocorbin-Kon,. 2015a. Probucol Release from Novel Multicompartmental Microcapsules for the Oral Targeted Delivery in Type 2 Diabetes. AAPS PharmSciTech. 16:45–52.
51. A.Mooranian, R.Negrulj, M.Mikov, S.Golocorbin-Kon, F.Arfuso, H.Al-Salami. 2015b. Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study. J Microencapsul (in press).
52. R.Negrulj, A.Mooranian, H.Al-Salami. 2013. Potentials and Limitations of Bile Acids in Type 2 Diabetes Mellitus:Applications of Microencapsulation as a Novel Oral Delivery System. J Endocrinol Diab Mellitus. 1:49–59.
53. R.Negrulj, A.Mooranian, N.Chen-Tan, H.S.Al-Sallami, M.Mikov, S.Golocorbin-Kon,. 2015. Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes. Artif Cells Nanomed Biotechnol. 1–8.
54. R.Pamies, R.R.Schmidt, M.D.C.L.Martínez, J.G.D.L.Torre. 2010. The influence of mono and divalent cations on dilute and non-dilute aqueous solutions of sodium alginates. Carbohydrate Polymers. 80:248–253.
55. M.J.Perez, O.Briz. 2009. Bile-acid-induced cell injury and protection. World J Gastroenterol. 15:1677–1689.
56. S.Prajapati, P.Tripathi, U.Ubaidulla, V.Anand. 2008. Design and development of gliclazide mucoadhesive microcapsules:in vitro and in vivo evaluation. AAPS PharmSciTech. 9:224–230.
57. J.Prawitt, S.Caron, B.Staels. 2011. Bile acid metabolism and the pathogenesis of type 2 diabetes. Curr Diab Rep. 11:160–166.
58. B.Renga, A.Mencarelli, P.Vavassori, V.Brancaleone, S.Fiorucci. 2010. The bile acid sensor FXR regulates insulin transcription and secretion. Biochim Biophys Acta Mol Basis Dis. 1802:363–372.
59. L.Rodes, A.Paul, M.Coussa-Charley, H.Al-Salami, C.Tomaro-Duchesneau, M.Fakhoury, S.Prakash. 2011. Transit time affects the community stability of lactobacillus and bifidobacterium species in an in vitro model of human colonic microbiotia. Artif Cells Blood Substit Immobil Biotechnol. 39:351–356.
60. B.Sarmento, D.Ferreira, F.Veiga, A.Ribeiro. 2006. Characterization of insulin-loaded alginate nanoparticles produced by ionotropic pre-gelation through DSC and FTIR studies. Carbohydr Polym. 66:1–7.
61. I.Sherman, M.Fisher. 1986. Hepatic transport of fluorescent molecules:in vivo studies using intravital TV microscopy. Hepatology. 6:444–449.
62. J.Soares, J.Santos, G.Chierice, E.Cavalheiro. 2004. Thermal behavior of alginic acid and its sodium salt. Eclética Química. 29:57–64.
63. M.Stojancevic, G.Bojic, H.A.Salami, M.Mikov. 2013. The Influence of Intestinal Tract and Probiotics on the Fate of Orally Administered Drugs. Curr Issues Mol Biol. 16:55–68.
64. S.Takka, A.G.Cali. 2012. Bile salt-reinforced alginate-chitosan beads. Pharm Dev Technol. 17:23–29.
65. D.Tanous, N.Hime, R.Stocker. 2008. Anti-atherosclerotic and anti- diabetic properties of probucol and related compounds. Redox Rep. 13:48–59.
66. C.Thomas, A.Gioiello, L.Noriega, A.Strehle, J.Oury, G.Rizzo,. 2009. TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis. Cell Metabolism. 10:167–177.
67. P.Thybo, B.L.Pedersen, L.Hovgaard, R.Holm, A.Müllertz. 2008. Characterization and Physical Stability of Spray Dried Solid Dispersions of Probucol and PVP-K30*. Pharm Dev Technol. 13:375–386.
68. J.M.Torpy, C.Lynm, R.M.Glass. 2009. DIabetes. JAMA. 301:1620–1620.
69. H.G.Xie, X.X.Li, G.J.Lv, W.Y.Xie, J.Zhu, T.Luxbacher,. 2010. Effect of surface wettability and charge on protein adsorption onto implantable alginate‐chitosan‐alginate microcapsule surfaces. J Biomed Mat Res Part A. 92:1357–1365.
70. S.Yamashita, Y.Matsuzawa. 2009. Where are we with probucol:a new life for an old drug? Atherosclerosis. 207:16–23.
71. L.Yang, Y.Xu, Y.Su, J.Wu, K.Zhao, J.Chen, M.Wang. 2005. FT-IR spectroscopic study on the variations of molecular structures of some carboxyl acids induced by free electron laser. Spectrochim Acta Part A, Mol Biomol Spectrosc. 62:1209–1215.
72. Y.Yang, O.H.Campanella, B.R.Hamaker, G.Zhang, Z.Gu. 2013. Rheological investigation of alginate chain interactions induced by concentrating calcium cations. Food Hydrocoll. 30:26–32.